<DOC>
	<DOCNO>NCT02932618</DOCNO>
	<brief_summary>The purpose study pediatric participant ( &lt; 18 year age ) severe hereditary von Willebrand disease ( VWD ) : 1 . To assess efficacy , safety , tolerability recombinant von Willebrand Factor ( rVWF ) , without ADVATE , treatment control nonsurgical bleeding event 2 . To assess efficacy safety rVWF ADVATE elective emergency surgery 3 . To determine pharmacokinetic ( PK ) profile rVWF</brief_summary>
	<brief_title>BAX 111 rVWF Pediatrics</brief_title>
	<detailed_description />
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>1 . Diagnosis severe von Willebrand disease ( VWD ) ( define von Willebrand factor : ristocetin cofactor [ VWF : RCo ] &lt; 20 % ) : 1 . Type 1 ( VWF : RCo &lt; 20 IU/dL ) ; 2 . Type 2A ( VWF : RCo &lt; 20 IU/dL ) , Type 2B ( diagnose genotype ) , Type 2N ( Factor VIII coagulation activity [ FVIII : C ] &lt; 10 % historically document genetics ) , Type 2M ; 3 . Type 3 ( VWF : Ag ≤3 IU/dL ) . 2 . Age 0 &lt; 18 year time Screening 3 . The participant provide assent ( appropriate ) legally authorize representative ( ) provide informed consent 4 . If female childbearing potential , participant present negative serum pregnancy test 5 . If applicable , participant agree employ adequate birth control measure duration study 6 . The participant and/or legal representative willing able comply requirement protocol Additional inclusion criterion previously treat participant participant undergo surgery follow : 1 . Unable tolerate inadequately responsive deaminodeltaDarginine vasopressin 2 . The participant minimum 1 document bleed require VWF coagulation factor replacement therapy previous 12 month prior enrollment overall historically 3 exposure day ( EDs ) plasmaderived VWF Additional inclusion criterion previously untreated participant follow : 1 . The participant receive prior VWF coagulation factor replacement therapy 1 . Diagnosis pseudoVWD another hereditary acquire coagulation disorder ( eg , qualitative quantitative platelet disorder elevate prothrombin time [ PT ] /international normalize ratio [ INR ] &gt; 1.4 ) 2 . History presence VWF inhibitor Screening 3 . History presence Factor VIII ( FVIII ) inhibitor titer ≥0.4 Bethesda unit ( BU ) ( Nijmegen assay ) ≥0.6 BU ( Bethesda assay ) 4 . Documented history VWF : RCo halflife &lt; 6 hour 5 . Known hypersensitivity component study drug , mouse hamster proteins 6 . Medical history immunological disorder , exclude seasonal allergic rhinitis/conjunctivitis/asthma , food allergy , animal allergy 7 . Medical history thromboembolic event 8 . Human immunodeficiency virus ( HIV ) positive , absolute CD4 count &lt; 200/mm^3 9 . In judgment Investigator , participant another clinically significant concomitant disease ( eg , uncontrolled hypertension , cancer ) may pose additional risk participant 10 . Diagnosis significant liver disease , evidence , limited , follow : serum alanine aminotransferase ( ALT ) 5 time upper limit normal ; hypoalbuminemia ; portal vein hypertension ( eg , presence otherwise unexplained splenomegaly , history esophageal varix ) liver cirrhosis classify Child B C 11 . Diagnosis renal disease , serum creatinine level ≥2.5 mg/dL 12 . Immunomodulatory drug treatment antiretroviral chemotherapy ( eg , αinterferon , corticosteroid agent dose equivalent hydrocortisone great 10 mg/day ( exclude topical treatment [ eg , ointment , nasal spray ] ) , within 30 day prior sign inform consent ( assent , appropriate ) 13 . If female , participant pregnant lactating time inform consent ( assent , appropriate ) obtain 14 . Participant participate another clinical study involve investigational product ( IP ) , recombinant von Willebrand Factor ( rVWF ) without ADVATE , investigational device within 30 day prior enrollment schedule participate another clinical study involve IP investigational device course study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>